MoneyWorks4Me

Lyka Labs informs about disclosure

10 Oct 2023 Evaluate
Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Lyka Labs has informed that, the Company has received the product permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w. The Company has received this permission after successfully completing the Clinical Trial on 125 patients across 8 Clinical Trial Centers within India.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1745.50
Dr. Reddys Labs. 1233.00
Cipla 1330.80
Lupin 1950.00
Zydus Lifesciences 1117.30
View more..